Sugi Predict

Sugi Predict / Compounds / SCHEMBL7185567

SCHEMBL7185567

SCHEMBL7185567

CCC(C)Oc1ccc(PC(=O)c2c(Cl)cccc2OC)c(C)c1.[LiH]

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35
▸ MAPT P10636 4/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ TAS1R3 Q7RTX0 1/20 0.34
▸ TAS1R1 Q7RTX1 1/20 0.34
▸ TAS1R2 Q8TE23 1/20 0.34
▸ ITGB1 P05556 1/20 0.34
▸ ITGA4 P13612 1/20 0.34
▸ CHRM2 P08172 1/20 0.33
▸ ACACB O00763 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ MTNR1A P48039 4/20 0.33
▸ MTNR1B P49286 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180661 0.94 HDAC1 (0.37) HDAC1HDAC2HDAC8MAPTALDH1A1
SCHEMBL7180691 0.94 SMN1; SMN2 (0.36) MAPTALDH1A1SMN1; SMN2ACACB
SCHEMBL7183488 0.91 HDAC1 (0.36) HDAC1HDAC2HDAC8MAPTSMN1; SMN2
SCHEMBL7187626 0.90 SMN1; SMN2 (0.34) MAPTALDH1A1SMN1; SMN2ITGB1ITGA4
SCHEMBL7182853 0.89 PNLIP (0.36) MAPTALDH1A1GAAL3MBTL1SMN1; SMN2
Lithium SCHEMBL7183495 0.88 HDAC1 (0.36) HDAC1HDAC2HDAC8MAPTSMN1; SMN2
SCHEMBL7182596 0.87 MAPT (0.43) MAPTALDH1A1GAAL3MBTL1SMN1; SMN2
Lithium SCHEMBL7190318 0.86 MAPT (0.35) MAPTALDH1A1GAAL3MBTL1SMN1; SMN2
SCHEMBL7174867 0.86 SMN1; SMN2 (0.46) HDAC8MAPTALDH1A1GAAL3MBTL1
Lithium SCHEMBL7177895 0.86 SMN1; SMN2 (0.35) MAPTALDH1A1GAAL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 HDAC1 1556/4885HDAC2 2156/4885HDAC8 1695/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 HDAC1 1870/4885HDAC2 1993/4885HDAC8 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.